Dr. David Sung Yong Kang is a medical adviser to Avedro Inc.

He is the only member in Asia.

▶View Advisory Committee List

http://avedro.com/about-us/medical-advisory-board/  

▶Related article

Avedro Granted Korean Approval for its KXL® Cross-Linking System for Lasik Xtra®

Waltham, Massachusetts, USA, Nov 07, 2014

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has been granted approval from the South Korean Ministry of Food and Drug Safety (MFDS, formerly the KFDA) for the company’s KXL Cross-Linking System. The KXL System components include the VibeX family of riboflavin formulations. The KXL device is designed to perform Lasik Xtra and accelerated cross-linking for keratoconus and post-LASIK ectasia.

Lasik Xtra is a three minute procedure performed in conjunction with standard LASIK to restore biomechanical integrity and strength to the cornea after a LASIK procedure. The procedure combines riboflavin ophthalmic solution with UVA irradiation from Avedro’s KXL device to achieve accelerated corneal cross-linking. For keratoconus and ectasia patients, accelerated cross-linking has the ability to halt progression of the condition in its early phases.

“Lasik Xtra offers the ability to ‘lock-in’ the treatment outcomes for both my LASIK and PRK patients, offering them additional peace of mind. As one of the early users of the technology in Korea, I’m excited to offer this improved procedure to my patients,” said David Sung Yong Kang, MD of the Eyereum Eye Clinic, Seoul, Korea. He added, “I’ve been asked to join the Avedro Medical Advisory Board and I’m looking forward to working with the Avedro team to develop new applications for corneal cross-linking.”

The approval of the KXL System is the culmination of a two-year effort working with the South Korean Ministry of Food and Drug Safety, which has one of the most comprehensive approval processes in the world.